ARA-290 dosage: chart, trial doses and vial math

How to mix a ARA-290 vial

These steps are for the 10 mg vial picked in the chart. Change the size there and the amounts here change with it.

1. Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
2. Draw 1 mL of bacteriostatic water into a syringe.
3. Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
4. Swirl the vial gently until the powder is gone. Do not shake it.
5. Write the date and 10 mg/mL on the vial, then put it in the fridge.

What ARA-290 is

ARA-290 (cibinetide) is a synthetic 11 amino acid peptide designed from the structure of erythropoietin. It acts on the innate repair receptor and was built to avoid erythropoietin's effect on red blood cells. [7]

Other names: ARA 290, ARA290, cibinetide.

How it has been given to people: injection under the skin in most trials; intravenous injection in the first pilot trial.

What to know before reading a dose

• Not an approved medicine in the US or Canada. Health Canada lists ARA 290 among unauthorized injectable peptide drugs seized from an online seller [12].
• Every human trial found was small, phase 2 and short. The largest had 64 subjects and the neuropathy trials dosed for 28 days.
• Employees of Araim Pharmaceuticals, the company developing the peptide, are authors on the main trial papers [2], [3], [4], [5].
• The dose that recurs in the trials is 4 mg once a day under the skin. In the one dose-ranging trial 8 mg did not do better than 4 mg on the main nerve fiber measure [4].
• Pain scores improved on placebo too in two of the trials [1], [4], so the pain findings are weaker than the nerve fiber findings.
• It leaves the blood fast: about 20 minutes after an injection under the skin, according to the trial group [7].
• The diabetic macular edema trial had 9 patients, no placebo group and no average improvement in vision [5].

Doses on record for ARA-290

Every dose below was given in a human study or printed on an approved label, and each links to its source. Doses set by body weight are left that way.

What the evidence shows

Each finding is tagged by the kind of study it comes from. Human trials are listed first.

Side effects and warnings

Reported in human studies or on a label:

• The 4-week intravenous pilot trial in sarcoidosis reported no safety concerns. [1]
• The abstract of the 28-day diabetes trial reports no safety issues. [3]
• The full text of the diabetes trial records four serious adverse events in the treated group. Two were judged unlikely to be related and two possibly related; one was worsening kidney function in a patient whose diuretic dose had been raised, and one patient died of a heart attack two weeks after the last dose, which the safety committee judged unrelated. [3]
• The 12-week trial in 9 patients with diabetic macular edema saw no serious adverse events and no antibodies to the peptide. [5]

ARA-290 has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.

Storage

Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.

ARA-290 dosage questions

Sources

Each one was opened on 10 Oct 2026 and matched to the line it supports.

1. Heij L et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012. PubMed 23168581.
2. Dahan A et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013. PubMed 24136731.
3. Brines M et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015. PubMed 25387363.
4. Culver DA et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci 2017. PubMed 28475703.
5. Lois N et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med 2020. PubMed 32674280.
6. Cerit H et al. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. Eur Neuropsychopharmacol 2015. PubMed 26431906.
7. Dahan A et al. Targeting the innate repair receptor to treat neuropathy. Pain Rep 2016. PubMed 29392190.
8. Araim Pharmaceuticals, Inc. A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis ClinicalTrials.gov 2014. clinicaltrials.gov. Trial NCT02039687.
9. US Food and Drug Administration Drugs@FDA and drug label searches via openFDA for cibinetide and ARA 290 (no match) 2026. api.fda.gov.
10. Health Canada Health Canada Drug Product Database, active ingredient searches: ara 290 and cibinetide (0 records) 2026. health-products.canada.ca.
11. US Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026. fda.gov.
12. Health Canada Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks 2025. recalls-rappels.canada.ca.
13. World Anti-Doping Agency The Prohibited List 2026. wada-ama.org.

Looked for and not found

• No approved product or label in the US or Canada, so no label dose, contraindications, interaction list or storage instructions.
• No phase 3 trial: PubMed and ClinicalTrials.gov searches for ARA 290 and cibinetide returned phase 2 work only.
• No published trial dosed it for longer than 12 weeks. The neuropathy trials all ran 28 days.
• The primary pharmacokinetic paper was not read. The half-life comes from a review by the trial group [7]; the diabetes trial's full text gives the same figure of about 20 minutes after 4 mg under the skin [3].
• The number enrolled in the 2015 diabetes trial is not in its abstract. The 2016 review by the same group gives 48 patients [7].
• Not named on the WADA Prohibited List (page checked 2026-10-11, [13]). The list has an open class, S0, for substances with no current approval by any governmental health authority; whether it applies to this compound was not determined here.

Change log

Related

BPC-157 dosageTB-500 dosageKPV dosageMGF dosageCartalax dosage10 mg vialWhat ARA-290 isHealing and recoveryPeptide dosage chartDosage calculator

DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.